Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5509320 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3GPR88 | |
| SCHEMBL1858676 | 0.85 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3598622 | 0.85 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1862381 | 0.84 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3620042 | 0.82 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3620044 | 0.82 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1861607 | 0.81 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1869695 | 0.80 | CHRNB2 (0.30) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1862797 | 0.79 | ANPEP (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3GPR88 | |
| SCHEMBL3612555 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | CHRNB2 4383/4885CHRNA4 4444/4885CHRNB4 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.